Intelligent Bio Solutions Inc. (INBS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $4.98M
Last updated: Nov 17, 2026 at 4:15 PM ET
Intelligent Bio Solutions Inc. (INBS) Statistics
Intelligent Bio Solutions (INBS) has a market cap of $4.98M. Its share count is up 262.15% from a year earlier. It kept -270.11% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $4.98M |
|---|---|
| Latest price (Nov 17, 2026) | $1.56 |
Key Dates
| Last Earnings Date | Nov 10, 2026 |
|---|---|
| Fiscal Year End | June |
Valuation Ratios
Sales and book value multiples are 1.1x and 0.6x.
| P/S Ratio | 1.1x |
|---|---|
| Forward P/S | 0.8x |
| P/B Ratio | 0.6x |
| P/TBV Ratio | 1.0x |
Price Statistics
The stock is down 78.34% over 52 weeks and trades 11.36% below its 50-day average.
| Beta (1Y) | 0.89 |
|---|---|
| 52-Week Change | -78.34% |
| 1-Month Change | +1.96% |
| 3-Month Change | -41.57% |
| 6-Month Change | -52.58% |
| 5-Year Change | -99.96% |
| Total Return (1Y) | -78.34% |
| Total Return (3Y CAGR) | -69.38% |
| Total Return (5Y CAGR) | -79.25% |
| Return vs SPY (1Y) | -88.95% |
| Max Drawdown (1Y) | -91.96% |
| Max Drawdown (3Y) | -97.87% |
| Sharpe Ratio (1Y) | -1.04 |
| Correlation with SPY (1Y) | 0.08 |
| 50-Day Average | $1.76 |
| 200-Day Average | $2.66 |
| 52-Week Range | $1.35 to $24.90 |
| RSI (14 Days) | 42.0 |
| Average Volume (20 Days) | 41.23K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.98x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.98x |
|---|---|
| Quick Ratio | 1.87x |
| Debt / Equity | 0.00x |
| Interest Coverage | -1482.43x |
Returns and Efficiency
Return on equity is -160.13% and return on assets is -89.14% over the last 12 months.
| Return on Equity (ROE) | -160.13% |
|---|---|
| Return on Assets (ROA) | -89.14% |
| ROA (5Y Average) | -95.48% |
| Asset Turnover | 0.38x |
| Inventory Turnover | 4.92x |
| Receivables Turnover | 4.86x |
| Cash Conversion Cycle | -496 days |
Scores
INBS has an Altman Z-Score of -9.76, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -9.76 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $4.50M over the last 12 months is up 36.55% from the 12 months before.
| Revenue | $4.50M |
|---|---|
| Revenue Growth (YoY) | +36.55% |
| Gross Profit | $2.29M |
| Operating Income | -$12.29M |
| Pretax Income | -$12.14M |
| Net Income | -$12.14M |
| EBITDA | -$10.81M |
| Reported EPS (TTM) | -$6.38 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 55.65% of the $13.62M in total assets.
| Cash and Equivalents | $5.93M |
|---|---|
| Total Debt | $0 |
| Net Cash | $5.93M |
| Net Cash Per Share | $1.92 |
| Working Capital | $4.47M |
| Shareholder Equity | $7.58M |
| Book Value Per Share | $2.45 |
| Tangible Book Value | $4.99M |
| Tangible Book Per Share | $1.61 |
| Total Assets | $13.62M |
| Total Liabilities | $6.27M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$11.83M |
|---|---|
| FCF Per Share | -$3.59 |
| Depreciation and Amortization | $1.44M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -273.43%.
| Gross Margin | 50.94% |
|---|---|
| Operating Margin | -273.43% |
| Pretax Margin | -270.11% |
| Net Margin | -270.11% |
| EBITDA Margin | -240.56% |
Growth
Revenue grew 49.68% a year over 3 years.
| Revenue Growth (3Y CAGR) | +49.68% |
|---|---|
| Revenue Growth (5Y CAGR) | +16.31% |
Dividends and Yields
INBS does not pay a dividend. Its free cash flow yield is -246.75%.
| FCF Yield | -246.75% |
|---|---|
| Buyback Yield | -242.11% |
| Shareholder Yield | -242.11% |
Stock Splits
The last split was a 1-for-10 reverse split on Dec 16, 2025.
| Last Split Date | Dec 16, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 7 similar companies, INBS has the 4th highest P/S.
P/S RatioPeer median 0.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +50.82%
| P/S Ratio | 1.1x vs 0.6x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +36.55% vs +50.82% median |
Analyst Forecast
Consensus estimates put revenue growth at 44.49% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +44.49% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About INBS
What is INBS's market cap?
Intelligent Bio Solutions has a market cap of $4.98M.
How many shares of INBS are outstanding?
Intelligent Bio Solutions has 3.10M shares outstanding. The count is up 262.15% from a year earlier.
Does INBS pay a dividend?
No. Intelligent Bio Solutions does not pay a dividend.
How much debt does INBS have?
Intelligent Bio Solutions has $0 of total debt and $5.93M of cash and equivalents, a net cash position of $5.93M.
INBS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors